|Trade names||Imodium, others|
|Other names||R-18553, Loperamide hydrochloride (USAN US)|
|Defined daily dose||10 mg|
|Elimination half-life||9–14 hours|
|Excretion||Faeces (30–40%), urine (1%)|
|Chemical and physical data|
|Molar mass||477.037 g/mol (513.506 with HCl) g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Loperamide, sold under the brand name Imodium, among others, is a medication used to decrease the frequency of diarrhea. It is often used for this purpose in gastroenteritis, inflammatory bowel disease, and short bowel syndrome. It is not recommended for those with blood in the stool. The medication is taken by mouth.
Common side effects include abdominal pain, constipation, sleepiness, vomiting, and a dry mouth. It may increase the risk of toxic megacolon. Loperamide's safety in pregnancy is unclear, but no evidence of harm has been found. It appears to be safe in breastfeeding. It is an opioid with no significant absorption from the gut and does not cross the blood–brain barrier when used at normal doses. It works by slowing the contractions of the intestines.
Loperamide was first made in 1969 and used medically in 1976. It is on the World Health Organization's List of Essential Medicines. Loperamide is available as an inexpensive generic medication. The wholesale cost in the developing world is about US$0.004 to 0.040 per dose. In August 2016, the US retail cost is about US$0.31 per dose. In 2017, it was the 351st most commonly prescribed medication in the United States, with more than 700 thousand prescriptions.
Loperamide is effective for the treatment of a number of types of diarrhea. This includes control of acute nonspecific diarrhea, mild traveler's diarrhea, irritable bowel syndrome, chronic diarrhea due to bowel resection, and chronic diarrhea secondary to inflammatory bowel disease. It is also useful for reducing ileostomy output. Off-label uses for loperamide also include chemotherapy-induced diarrhea, especially related to irinotecan use.
In may be used in children over the age of 2 years old with the dose depending on a child's weight and age. For those 2 to 5 years old the dose is 1 mg three times per day, for those 6 to 8 year old, 2 mg twice per day, and for those over 8 years, 2 mg three times per day.
Side effects most commonly associated with loperamide are constipation (which occurs in 1.7–5.3% of users), dizziness (up to 1.4%), nausea (0.7–3.2%), and abdominal cramps (0.5–3.0%). Rare, but more serious, side effects include toxic megacolon, paralytic ileus, angioedema, anaphylaxis/allergic reactions, toxic epidermal necrolysis, Stevens–Johnson syndrome, erythema multiforme, urinary retention, and heat stroke. The most frequent symptoms of loperamide overdose are drowsiness, vomiting, and abdominal pain, or burning. High doses may result in heart problems such as abnormal heart rhythms.
Treatment should be avoided in the presence of high fever or if the stool is bloody. Treatment is not recommended for people who could have negative effects from rebound constipation. If a suspicion exists of diarrhea associated with organisms that can penetrate the intestinal walls, such as E. coli O157:H7 or Salmonella, loperamide is contraindicated as a primary treatment. Loperamide treatment is not used in symptomatic C. difficile infections, as it increases the risk of toxin retention and precipitation of toxic megacolon.
Loperamide should be administered with caution to people with liver failure due to reduced first-pass metabolism. Additionally, caution should be used when treating people with advanced HIV/AIDS, as cases of both viral and bacterial toxic megacolon have been reported. If abdominal distension is noted, therapy with loperamide should be discontinued.
The use of loperamide in children under two years is not recommended. Rare reports of fatal paralytic ileus associated with abdominal distention have been made. Most of these reports occurred in the setting of acute dysentery, overdose, and with very young children less than two years of age. A review of loperamide in children under 12 years old found that serious adverse events occurred only in children under three years old. The study reported that the use of loperamide should be contraindicated in children who are under 3, systemically ill, malnourished, moderately dehydrated, or have bloody diarrhea. In 1990, all formulations for children of the antidiarrheal loperamide were banned in Pakistan.
Pregnancy and breast feeding
Loperamide is not recommended in the United Kingdom for use during pregnancy or by nursing mothers. In the U.S., loperamide is classified by the U.S. Food and Drug Administration (FDA) as pregnancy category C. Studies in rat models have shown no teratogenicity, but sufficient studies in humans have not been conducted. One controlled, prospective study of 89 women exposed to loperamide during their first trimester of pregnancy showed no increased risk of malformations. This, however, was only one study with a small sample size. Loperamide can be present in breast milk, and is not recommended for breast-feeding mothers.
Loperamide is a substrate of P-glycoprotein; therefore, the concentration of loperamide increases when given with a P-glycoprotein inhibitor. Common P-glycoprotein inhibitors include quinidine, ritonavir, and ketoconazole. Loperamide is capable of decreasing the absorption of some other drugs. As an example, saquinavir concentrations can decrease by half when given with loperamide.
Loperamide is an antidiarrheal agent, which decreases intestinal movement. As such, when combined with other antimotility drugs, the risk of constipation is increased. These drugs include other opioids, antihistamines, antipsychotics, and anticholinergics.
Mechanism of action
Loperamide is an opioid-receptor agonist and acts on the μ-opioid receptors in the myenteric plexus of the large intestine. It works like morphine, decreasing the activity of the myenteric plexus, which decreases the tone of the longitudinal and circular smooth muscles of the intestinal wall. This increases the time material stays in the intestine, allowing more water to be absorbed from the fecal matter. It also decreases colonic mass movements and suppresses the gastrocolic reflex.
Loperamide's circulation in the bloodstream is limited in two ways. Efflux by P-glycoprotein in the intestinal wall reduces passage of loperamide, and the fraction of drug crossing is then further reduced through first-pass metabolism by the liver. Loperamide metabolizes into an MPTP-like compound, but is unlikely to exert neurotoxicity.
Efflux by P-glycoprotein also prevents circulating loperamide from effectively crossing the blood–brain barrier, so it can generally only antagonize muscarinic receptors in the peripheral nervous system, and currently has a score of one on the anticholinergic cognitive burden scale. Concurrent administration of P-glycoprotein inhibitors such as quinidine potentially allows loperamide to cross the blood–brain barrier and produce central morphine-like effects. Loperamide taken with quinidine was found to produce respiratory depression, indicative of central opioid action.
Loperamide has been shown to cause a mild physical dependence during preclinical studies, specifically in mice, rats, and rhesus monkeys. Symptoms of mild opiate withdrawal were observed following abrupt discontinuation of long-term treatment of animals with loperamide.
When originally approved for medical use in the United States, loperamide was considered a narcotic and was put into Schedule II of the Controlled Substances Act 1970. It was transferred to Schedule V on 17 July 1977, and then decontrolled on 3 November 1982.
Loperamide hydrochloride was first synthesized in 1969  by Paul Janssen from Janssen Pharmaceutica in Beerse, Belgium, following previous discoveries of diphenoxylate hydrochloride (1956) and fentanyl citrate (1960).
The first clinical reports on loperamide were published in 1973 in the Journal of Medicinal Chemistry with the inventor being one of the authors. The trial name for it was "R-18553". Loperamide oxide has a different research code: R-58425.
During the 1980s, Imodium became the best-selling prescription antidiarrheal in the United States.
In the 1980s, loperamide also existed in the form of drops (Imodium Drops) and syrup. Initially, it was intended for children's usage, but Johnson & Johnson voluntarily withdrew it from the market in 1990 after 18 cases of paralytic ileus (resulting in six deaths) were registered in Pakistan and reported by the World Health Organization (WHO). In the following years (1990-1991), products containing loperamide have been restricted for children's use in a number of countries (ranging from two to five years of age).
In the late 1980s, before the US patent expired on 30 January 1990, McNeil company started to develop Imodium Advanced containing loperamide and simethicone for treating both diarrhea and gas. In March 1997, the company patented such combination. The drug was approved in June 1997, by the FDA as Imodium Multi-Symptom Relief in the form of a chewable tablet.
Society and culture
It is sold as a generic medication and is not very expensive. The wholesale cost in the developing world is about US$0.004 to 0.040 a dose. In August 2016, the US retail cost is about $0.31 per dose. In 2016, Imodium was one of the biggest-selling branded over-the-counter medications sold in Great Britain, with sales of £32.7 million.
Loperamide was originally marketed as Imodium, and many generic brands are sold.
Loperamide has typically been deemed to have a relatively low risk of misuse. In 2012, no reports of loperamide abuse were made. In 2015, however, case reports of extremely high-dose loperamide use were published. Primary intent of users has been to manage symptoms of opioid withdrawal such as diarrhea, although a small portion derive psychoactive effects at these higher doses. At these higher doses central nervous system penetrance occurs and long term use may lead to tolerance, dependence, and withdrawal on abrupt cessation. Dubbing it "the poor man's methadone", clinicians warned that increased restrictions on the availability of prescription opioids passed in response to the opioid epidemic were prompting recreational users to turn to loperamide as an over-the-counter treatment for withdrawal symptoms. The FDA responded to these warnings by calling on drug manufacturers to voluntarily limit the availability of loperamide for public-safety reasons, in an analogous manner to restrictions put on the sales of pseudoephedrine, to be sold only in limited amounts. Since 2015, several reports of sometimes-fatal cardiotoxicity due to high-dose loperamide abuse have been published.
- Methylnaltrexone, another peripheral-acting opioid antagonist, is similar to naloxegol (indicated to reduce OIC without greatly affecting analgesia).
- Naloxegol, a peripheral-acting opioid antagonist, is indicated to reduce opioid-induced constipation (OIC) without greatly affecting analgesia. As such, it can be considered the antithesis of the peripheral-acting opiate agonist loperamide.
- Simethicone, a silicone unrelated to opioids, is combined with loperamide in some formulations. It is an antifoaming agent used to reduce bloating, discomfort, or pain caused by excessive gas.
- Drugs.com International brands for loperamide Archived 23 September 2015 at the Wayback Machine Page accessed Sept 4, 2015
- "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 31 August 2020.
- "Loperamide Hydrochloride". The American Society of Health-System Pharmacists. Archived from the original on 7 September 2015. Retrieved 25 August 2015.
- "Prescribing medicines in pregnancy database". Australian Government. 3 March 2014. Archived from the original on 8 April 2014. Retrieved 22 April 2014.
- "Loperamide use while Breastfeeding". Archived from the original on 8 September 2015. Retrieved 26 August 2015.
- "loperamide hydrochloride". NCI Drug Dictionary. 2 February 2011. Archived from the original on 7 September 2015. Retrieved 26 August 2015.
- Patrick, Graham L. (2013). An introduction to medicinal chemistry (Fifth ed.). Oxford: Oxford University Press. p. 644. ISBN 9780199697397.
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- Hamilton, Richard J. (2013). Tarascon pocket pharmacopoeia (14 ed.). [Sudbury, Mass.]: Jones & Bartlett Learning. p. 217. ISBN 9781449673611. Archived from the original on 5 March 2016.
- "Loperamide HCL". International Drug Price Indicator Guide. Archived from the original on 10 May 2017. Retrieved 26 August 2015.
- "NADAC (National Average Drug Acquisition Cost) Loperamide". Centers for Medicare and Medicaid Services. Archived from the original on 12 August 2016. Retrieved 16 April 2016.
Loperamide 2mg Capsule ... 0.33803 [USD] ... 03/23/2016
- "Loperamide Hydrochloride - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.
- Hanauer, S. B. (Winter 2008). "The Role of Loperamide in Gastrointestinal Disorders". Reviews in Gastroenterological Disorders. 8 (1): 15–20. PMID 18477966.
- "Loperamide". Archived from the original on 20 May 2016. Retrieved 14 May 2016.
- Miftahof, Roustem (2009). Mathematical Modeling and Simulation in Enteric Neurobiology. World Scientific. p. 18. ISBN 9789812834812. Archived from the original on 28 July 2017.
- Benson, Al; Chakravarthy, A.; Hamilton, Stanley R.; et al., eds. (2013). Cancers of the Colon and Rectum: A Multidisciplinary Approach to Diagnosis and Management. Demos Medical Publishing. p. 225. ISBN 9781936287581. Archived from the original on 8 September 2017.
- Zuckerman, Jane N. (2012). Principles and Practice of Travel Medicine. John Wiley & Sons. p. 203. ISBN 9781118392089. Archived from the original on 8 September 2017.
- "Loperamide - WikEM". www.wikem.org. Retrieved 9 August 2020.
- "LOPERAMIDE oral - Essential drugs". medicalguidelines.msf.org. Retrieved 31 August 2020.
- "Imodium label" (PDF). U.S. Food and Drug Administration (FDA). Archived (PDF) from the original on 23 April 2014. Retrieved 21 April 2014.
- "Epocrates Page Not Found". Archived from the original on 1 November 2018. Retrieved 14 May 2016. Cite uses generic title (help)
- Litovitz, T; Clancy, C; Korberly, B; Temple, AR; Mann, KV (1997). "Surveillance of loperamide ingestions: an analysis of 216 poison center reports". Journal of Toxicology. Clinical Toxicology. 35 (1): 11–9. doi:10.3109/15563659709001159. PMID 9022646.
- "Safety Alerts for Human Medical Products - Loperamide (Imodium): Drug Safety Communication - Serious Heart Problems With High Doses From Abuse and Misuse". U.S. Food and Drug Administration (FDA). Archived from the original on 11 June 2016. Retrieved 12 June 2016.
- "rxlist.com". 2005. Archived from the original on 27 November 2012.
- "Drugs@FDA: FDA Approved Drug Products". U.S. Food and Drug Administration (FDA). Archived from the original on 6 May 2016. Retrieved 14 May 2016.
- "Imodium (Loperamide Hydrochloride) Capsule". DailyMed. NIH. Archived from the original on 13 April 2010.
- Li ST, Grossman DC, Cummings P (2007). "Loperamide therapy for acute diarrhea in children: systematic review and meta-analysis". PLOS Medicine. 4 (3): e98. doi:10.1371/journal.pmed.0040098. PMC 1831735. PMID 17388664.
- "E-DRUG: Chlormezanone". Essentialdrugs.org. Archived from the original on 26 July 2011.
- "Medicines information links - NHS Choices". Archived from the original on 10 January 2014. Retrieved 14 May 2016.
- "Drugs@FDA: FDA Approved Drug Products". U.S. Food and Drug Administration (FDA). Archived from the original on 6 May 2016. Retrieved 14 May 2016.
- Einarson, A.; et al. (2000). "Prospective, controlled, multicentre study of loperamide in pregnancy". Canadian Journal of Gastroenterology. 14 (3): 185–187. doi:10.1155/2000/957649. PMID 10758415.
- "Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers". U.S. Food and Drug Administration (FDA). Archived from the original on 10 May 2016. Retrieved 14 May 2016.
- "Epocrates Page Not Found". Retrieved 14 May 2016. Cite uses generic title (help)
- "DrugBank: Loperamide". Archived from the original on 10 May 2016. Retrieved 14 May 2016.
- "Loperamide Hydrochloride Drug Information, Professional". Archived from the original on 3 May 2016. Retrieved 14 May 2016.
- Katzung, B. G. (2004). Basic and Clinical Pharmacology (9th ed.). ISBN 978-0-07-141092-2.[page needed]
- Lemke, Thomas L.; Williams, David A. (2008). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. p. 675. ISBN 9780781768795. Archived from the original on 8 September 2017.
- Dufek, Matthew B.; Knight, Beverly M.; Bridges, Arlene S.; Thakker, Dhiren R. (1 March 2013). "P-glycoprotein increases portal bioavailability of loperamide in mouse by reducing first-pass intestinal metabolism". Drug Metabolism and Disposition. 41 (3): 642–650. doi:10.1124/dmd.112.049965. ISSN 1521-009X. PMID 23288866.
- Kalgutkar, Amit S.; Nguyen, Hang T. (1 September 2004). "Identification of an N-Methyl-4-Phenylpyridinium-Like Metabolite of the Antidiarrheal Agent Loperamide in Human Liver Microsomes: Underlying Reason(s) for the Lack of Neurotoxicity Despite the Bioactivation Event". Drug Metabolism and Disposition. 32 (9): 943–952. ISSN 0090-9556. PMID 15319335. Archived from the original on 8 September 2017.
- Upton, RN (August 2007). "Cerebral uptake of drugs in humans". Clinical and Experimental Pharmacology & Physiology. 34 (8): 695–701. doi:10.1111/j.1440-1681.2007.04649.x. PMID 17600543.
- "Anticholinergic Cognitive Burden Scale" (PDF). Archived from the original (PDF) on 7 March 2018. Retrieved 23 September 2017.
- Sadeque, A. J.; Wandel, C.; He, H.; Shah, S.; Wood, A. J. (September 2000). "Increased Drug Delivery to the Brain by P-glycoprotein Inhibition". Clinical Pharmacology and Therapeutics. 68 (3): 231–237. doi:10.1067/mcp.2000.109156. PMID 11014404.
- Yanagita, T.; Miyasato, K.; Sato, J. (1979). "Dependence Potential of Loperamide Studied in Rhesus Monkeys". NIDA Research Monograph. 27: 106–113. PMID 121326.
- Nakamura, H.; Ishii, K.; Yokoyama, Y.; et al. (November 1982). "[Physical Dependence on Loperamide Hydrochloride in Mice and Rats]". Yakugaku Zasshi (in Japanese). 102 (11): 1074–1085. doi:10.1248/yakushi1947.102.11_1074. PMID 6892112.CS1 maint: unrecognized language (link)
- "DEA "Orange Book" Lists of Scheduling Actions" (PDF). DEA Office of Diversion Control. U.S. Department of Justice. February 2016. Archived (PDF) from the original on 17 April 2016. Retrieved 17 April 2016.
- Florey, Klaus (1991). Profiles of Drug Substances, Excipients and Related Methodology, Volume 19. Academic Press. p. 342. ISBN 9780080861142.
- Stokbroekx RA, Vandenberk J, Van Heertum AH, Van Laar GM, Van der Aa MJ, Van Bever WF, Janssen PA (1973). "Synthetic Antidiarrheal Agents. 2,2-Diphenyl-4-(4'-aryl-4'-hydroxypiperidino)butyramides". Journal of Medicinal Chemistry. 16 (7): 782–786. doi:10.1021/jm00265a009. PMID 4725924.
- Schuermans V, Van Lommel R, Dom J, Brugmans J (1974). "Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 6: Clinical pharmacology. Placebo-controlled comparison of the constipating activity and safety of loperamide, diphenoxylate and codeine in normal volunteers". Arzneimittelforschung. 24 (10): 1653–7. PMID 4611432.
- "Compound Report Card". Archived from the original on 11 August 2016. Retrieved 23 June 2016.
- P. Mainguet; R. Fiasse (1977). "Double-blind placebo-controlled study of loperamide (Imodium) in chronic diarrhoea caused by ileocolic disease or resection" (PDF). Gut. 18 (7): 575–579. doi:10.1136/gut.18.7.575. PMC 1411573. PMID 326642. Archived from the original (PDF) on 6 September 2014. Retrieved 2014-09-05.
- "IMODIUM FDA Application No.(NDA) 017694". U.S. Food and Drug Administration (FDA). 1976. Archived from the original on 13 August 2014. Retrieved 2014-09-05.
- McNeil-PPC, Inc., Plaintiff, v. L. Perrigo Company, and Perrigo Company, Defendants, 207 F. Supp. 2d 356 (E.D. Pa. 25 June 2002).
- "IMODIUM A-D FDA Application No.(NDA) 019487". U.S. Food and Drug Administration (FDA). 1988. Archived from the original on 13 August 2014. Retrieved 2014-09-05.
- "Loperamide: voluntary withdrawal of infant fomulations" (PDF). WHO Drug Information. 4 (2): 73–74. 1990. Archived from the original (PDF) on 7 September 2014. Retrieved 2014-09-06.
The leading international supplier of this preparation, Johnson and Johnson, has since informed WHO that having regard to the dangers inherent in improper use and overdosing, this formulation (Imodium Drops), was voluntarily withdrawn from Pakistan in March 1990. The company has since decided not only to withdraw this preparation worldwide, but also to remove all syrup formulations from countries where WHO has a programme for control of diarrhoeal diseases.
- Consolidated List of Products Whose Consumption And/or Sale Have Been Banned, Withdrawn, Severely Restricted Or Not Approved by Governments, 8th Issue. United Nations. 2003. pp. 130–131. ISBN 978-92-1-130230-1. Archived from the original on 8 September 2017.
- US patent 5612054, Jeffrey L. Garwin, "Pharmaceutical compositions for treating gastrointestinal distress", issued 1997-03-18, assigned to McNeil-PPC, Inc.
- "IMODIUM MULTI-SYMPTOM RELIEF FDA Application No.(NDA) 020606". U.S. Food and Drug Administration (FDA). 1997. Archived from the original on 13 August 2014. Retrieved 2014-09-05.
- "Scherer announces launch of another product utilizing its Zydis technology". PR Newswire Association LLC. 9 November 1993. Archived from the original on 30 August 2014. Retrieved 30 August 2014.
- Rathbone, Michael J.; Hadgraft, Jonathan; Roberts, Michael S. (2002). "The Zydis Oral Fast-Dissolving Dosage Form". Modified-Release Drug Delivery Technology. CRC Press. p. 200. ISBN 9780824708696. Retrieved 26 August 2014.
- World Health Organization (2014). The selection and use of essential medicines: report of the WHO Expert Committee, 2013 (including the 18th WHO model list of essential medicines and the 4th WHO model list of essential medicines for children). Geneva: World Health Organization. hdl:10665/112729. ISBN 9789241209854. ISSN 0512-3054. WHO technical report series;985.
- Connelly D (April 2017). "A breakdown of the over-the-counter medicines market in Britain in 2016". The Pharmaceutical Journal. Royal Pharmaceutical Society. 298 (7900). doi:10.1211/pj.2017.20202662. ISSN 2053-6186.
- Baker, DE (2007). "Loperamide: a pharmacological review". Reviews in Gastroenterological Disorders. 7 (Suppl 3): S11–8. PMID 18192961.
- Mediators and Drugs in Gastrointestinal Motility II: Endogenous and Exogenous Agents. Springer Science & Business Media. 6 December 2012. pp. 290–. ISBN 978-3-642-68474-6.
- MacDonald, R; Heiner, J; Villarreal, J; Strote, J (2 May 2015). "Loperamide dependence and abuse". BMJ Case Reports. 2015: bcr2015209705. doi:10.1136/bcr-2015-209705. PMC 4434293. PMID 25935922.
- Dierksen, Jennifer; Gonsoulin, Morna; Walterscheid, Jeffrey P. (2015). "Poor Manʼs Methadone". The American Journal of Forensic Medicine and Pathology. 36 (4): 268–270. doi:10.1097/PAF.0000000000000201. ISSN 0195-7910. PMID 26355852.
- Stanciu, CN; Gnanasegaram, SA (2017). "Loperamide, the "Poor Man's Methadone": Brief Review". Journal of Psychoactive Drugs. 49 (1): 18–21. doi:10.1080/02791072.2016.1260188. PMID 27918873.
- Guarino, Ben (4 May 2016). "Abuse of diarrhea medicine you know well is alarming physicians". Washington Post. Retrieved 6 May 2016.
- McGinley, Laurie (30 January 2018). "FDA wants to curb abuse of Imodium, 'the poor man's methadone'". Washington Post. ISSN 0190-8286. Retrieved 30 January 2018.
- Commissioner, Office of the. "Safety Alerts for Human Medical Products - Imodium (loperamide) for Over-the-Counter Use: Drug Safety Communication - FDA Limits Packaging To Encourage Safe Use". U.S. Food and Drug Administration (FDA). Retrieved 2 February 2018.
- Eggleston, William; Clark, Kenneth H.; Marraffa, Jeanna M. (2016). "Loperamide Abuse Associated With Cardiac Dysrhythmia and Death". Annals of Emergency Medicine. 69 (1): 83–86. doi:10.1016/j.annemergmed.2016.03.047. ISSN 0196-0644. PMID 27140747.
- Mukarram, O.; Hindi, Y.; Catalasan, G.; Ward, J. (2016). "Loperamide Induced Torsades de Pointes: A Case Report and Review of the Literature". Case Reports in Medicine. 2016: 1–3. doi:10.1155/2016/4061980. ISSN 1687-9627. PMC 4775784. PMID 26989420.